The short version
- Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- What the evidence isApproved with large outcome trials.
- What to watchFainting or lightheadedness on standing.
How Losartan works
Losartan blocks a receptor. That one word is the whole difference between this drug and an ACE inhibitor, and everything practical about it falls out of the word.
The consequence the label states outright is that angiotensin II does not fall — it rises. Removing the negative feedback causes a doubling to tripling of plasma renin activity and a consequent rise in angiotensin II plasma concentration U.S. Food and Drug Administration 2025.
- Oral
Research on Losartan7 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
Approved with large outcome trials. LIFE (9,193 patients) compared it against atenolol in hypertension with left ventricular hypertrophy and showed fewer strokes despite similar blood pressure reduction. RENAAL showed reduced progression of diabetic nephropathy.
A trial in Marfan syndrome tested it against atenolol for aortic root dilation, on the TGF-beta rationale, and found no clear superiority — a worthwhile example of a mechanistically elegant hypothesis not carrying through.
Correlative data
Very wide prescribing. No cough, which is its main practical advantage over ACE inhibitors and the usual reason for a switch.
It has a mild uricosuric effect — unique among ARBs — which makes it the preferred choice in someone with gout, a small but genuinely useful detail.
How the mechanism reads
Blocks the angiotensin II type 1 receptor rather than the enzyme that makes angiotensin II.
MechanisticBlocking downstream instead of upstream is the whole design difference. Bradykinin is not affected, so no cough. Angiotensin II still rises and can act on the AT2 receptor, which may itself be beneficial.
MechanisticIt is a prodrug converted by CYP2C9 to a metabolite roughly ten to forty times more potent — which predicts variable response in people with reduced CYP2C9 activity.
Mechanistic
Sources
- U.S. Food and Drug Administration. COZAAR (losartan potassium) tablets, for oral use - full prescribing information (NDA 020386).. FDA approved labeling, revision 2025
- Dahlöf B. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.. Lancet 2002 · PMID 11937178
- Brenner BM. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.. N Engl J Med 2001 · PMID 11565518
- Hamada T. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.. Am J Hypertens 2008 · PMID 18670416
- Lacro RV. Atenolol versus losartan in children and young adults with Marfan's syndrome.. N Engl J Med 2014 · PMID 25405392
- Lo MW. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.. Clin Pharmacol Ther 1995 · PMID 8529329
- Vanderheyden PM. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.. Br J Pharmacol 1999 · PMID 10193788
Losartan safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Pregnancy, with a boxed warning for fetal injury and death.
- Tight narrowing of the arteries to both kidneys, where angiotensin blockade collapses filtration.
- Potassium supplements or potassium-sparing diuretics.
- Dehydration or heavy fluid loss.
- Taking aliskiren if you have diabetes.
What’s expected
- Blood pressure falls as angiotensin II receptors are blocked.
- Uric acid falls because losartan is also uricosuric.
- Dizziness, and a small rise in potassium.
Watch for
- Fainting or lightheadedness on standing.
- Very little urine.
- Lip or face swelling, rare with ARBs.
Labs that tell you it’s working
- Uric Acid: its uricosuric action on URAT1 lowers it, unlike other ARBs.
- Comprehensive Metabolic Panel: potassium and creatinine.
- Cystatin C with eGFR: tracks kidney protection in diabetic nephropathy trials.
Angiotensin II receptor blocker with an extra uricosuric effect through URAT1; fetal toxicity is the boxed warning. PMID 18670416 PMID 11565518
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Losartan FAQ4 common questions
- Is Losartan approved for human use?
- No. Losartan is a research compound.
- What is Losartan researched for?
- Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- Which labs show whether it's doing anything?
- Uric Acid; Comprehensive Metabolic Panel; Cystatin C with eGFR: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Losartan: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



